Dyne Therapeutics (DYN) Short Interest Ratio & Short Volume $11.19 -0.40 (-3.45%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$11.78 +0.59 (+5.31%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Dyne Therapeutics Short Interest DataDyne Therapeutics (DYN) has a short interest of 15.73 million shares. This marks a -3.91% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.5, indicating that it would take 5.5 days of the average trading volume of 3.18 million shares to cover all short positions.Current Short Interest15,730,000 sharesPrevious Short Interest16,370,000 sharesChange Vs. Previous Month-3.91%Dollar Volume Sold Short$130.24 millionShort Interest Ratio5.5 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares142,264,000 sharesPercentage of Shares Shorted11.06%Today's Trading Volume3,613,307 sharesAverage Trading Volume3,179,195 sharesToday's Volume Vs. Average114% Short Selling Dyne Therapeutics? Sign up to receive the latest short interest report for Dyne Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDYN Short Interest Over TimeDYN Days to Cover Over TimeDYN Percentage of Float Shorted Over Time Dyne Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202515,730,000 shares $130.24 million -3.9%N/A5.5 $8.28 6/30/202516,370,000 shares $155.84 million -20.6%16.8%5.6 $9.52 6/15/202520,620,000 shares $297.13 million -19.2%21.1%7.7 $14.41 5/31/202525,530,000 shares $301.76 million +10.0%31.7%10.3 $11.82 5/15/202523,200,000 shares $272.37 million +56.1%28.8%9.5 $11.74 4/30/202514,860,000 shares $175.20 million -2.7%N/A6.3 $11.79 4/15/202515,270,000 shares $119.87 million +34.7%18.9%6.8 $7.85 3/31/202511,340,000 shares $118.62 million -8.4%14.1%4.8 $10.46 3/15/202512,380,000 shares $149.18 million +6.1%15.4%6.2 $12.05 2/28/202511,670,000 shares $158.83 million +7.1%14.5%6.4 $13.61 Get the Latest News and Ratings for DYN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202510,900,000 shares $151.62 million +14.0%13.5%6.4 $13.91 1/31/20259,560,000 shares $135.94 million +1.7%N/A5.7 $14.22 1/15/20259,400,000 shares $146.08 million -10.7%N/A6.1 $15.54 12/31/202410,520,000 shares $247.85 million +1.2%N/A9.8 $23.56 12/15/202410,400,000 shares $267.59 million +0.5%N/A11.2 $25.73 11/30/202410,350,000 shares $316.81 million +2.0%N/A10 $30.61 11/15/202410,150,000 shares $288.16 million +2.1%N/A7.9 $28.39 10/31/20249,940,000 shares $286.87 million +9.1%N/A8.1 $28.86 10/15/20249,110,000 shares $306.00 million +2.6%N/A7.3 $33.59 9/30/20248,880,000 shares $318.97 million +15.9%N/A6.9 $35.92 9/15/20247,660,000 shares $260.90 million +11.5%N/A5.7 $34.06 8/31/20246,870,000 shares $316.64 million -6.9%N/A5.4 $46.09 8/15/20247,380,000 shares $337.56 million -25.3%N/A6.7 $45.74 7/31/20249,880,000 shares $423.95 million +6.9%N/A7.8 $42.91 7/15/20249,240,000 shares $400.46 million +1.8%N/A7.6 $43.34 6/30/20249,080,000 shares $320.43 million -9.5%N/A7.6 $35.29 6/15/202410,030,000 shares $331.69 million -0.8%N/A8.2 $33.07 5/31/202410,110,000 shares $322.31 million +8.0%N/A7.8 $31.88 5/15/20249,360,000 shares $275.00 million -2.8%N/A6.6 $29.38 4/30/20249,630,000 shares $243.74 million +6.8%18.9%7.8 $25.31 4/15/20249,020,000 shares $229.47 million +11.6%N/A6.5 $25.44 3/31/20248,080,000 shares $229.39 million +18.5%16.2%4.7 $28.39 3/15/20246,820,000 shares $190.89 million +3.2%13.7%3.2 $27.99 2/29/20246,610,000 shares $177.81 million -8.8%16.6%3.3 $26.90 2/15/20247,250,000 shares $171.10 million -15.2%19.1%4 $23.60 1/31/20248,550,000 shares $182.97 million +7.3%28.8%4.9 $21.40 1/15/20247,970,000 shares $133.02 million -18.5%26.8%5.1 $16.69 6/30/20235,480,000 shares $61.65 million +12.5%17.0%10.2 $11.25 6/15/20234,870,000 shares $58.93 million -1.4%15.1%9.4 $12.10 5/31/20234,940,000 shares $64.37 million -1.0%15.8%12.1 $13.03Washington Thinks They Own Your Bank Account (Ad)What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.Get your free guide now by clicking here >> 5/15/20234,990,000 shares $68.31 million +2.3%16.0%12.6 $13.69 4/30/20234,880,000 shares $50.56 million No Change15.3%13 $10.36 4/15/20234,880,000 shares $44.41 million +14.0%15.3%15.3 $9.10 3/31/20234,280,000 shares $49.31 million +5.2%13.5%12.5 $11.52 3/15/20234,070,000 shares $51.40 million +8.0%13.6%13.6 $12.63 2/28/20233,770,000 shares $48.56 million +1.9%12.7%11.4 $12.88 2/15/20233,700,000 shares $50.62 million +4.2%13.4%11.7 $13.68 1/31/20233,550,000 shares $51.83 million +25.0%13.0%11.7 $14.60 1/15/20232,840,000 shares $36.81 million +15.9%10.4%9.5 $12.96 12/30/20222,450,000 shares $28.40 million -11.2%8.9%8.7 $11.59 12/15/20222,760,000 shares $37.51 million +2.2%9.7%9 $13.59 11/30/20222,700,000 shares $31.59 million -5.3%9.5%11.1 $11.70 11/15/20222,850,000 shares $28.47 million +2.5%10.1%11.1 $9.99 10/31/20222,780,000 shares $31.69 million +23.6%9.7%10.3 $11.40 10/15/20222,250,000 shares $29.68 million +27.8%7.9%8.3 $13.19 9/30/20221,760,000 shares $22.35 million +38.6%6.2%6.7 $12.70 9/15/20221,270,000 shares $17.78 million +5.8%4.6%5.2 $14.00 8/31/20221,200,000 shares $11.76 million +17.7%4.4%5.1 $9.80 8/15/20221,020,000 shares $12.23 million +16.4%3.7%4.8 $11.99 7/31/2022876,500 shares $9.19 million -14.9%3.3%4.7 $10.49 7/15/20221,030,000 shares $10.56 million -73.0%3.8%5.8 $10.25 6/30/20223,820,000 shares $26.24 million +1.1%14.2%22.9 $6.87 6/15/20223,780,000 shares $20.87 million +139.2%14.0%23.2 $5.52 5/31/20221,580,000 shares $7.60 million -3.1%5.9%10.1 $4.81 5/15/20221,630,000 shares $9.10 million -2.4%6.1%10.4 $5.58 4/30/20221,670,000 shares $13.33 million +1.2%6.2%10.3 $7.98 4/15/20221,650,000 shares $15.81 million +1.2%6.1%8.6 $9.58 3/31/20221,630,000 shares $15.71 million -3.0%6.2%6.8 $9.64 3/15/20221,680,000 shares $14.50 million -28.8%6.4%7.1 $8.63 2/28/20222,360,000 shares $20.23 million +3.1%9.0%9.8 $8.57 2/15/20222,290,000 shares $17.04 million +5.5%8.7%9.2 $7.44 1/31/20222,170,000 shares $16.10 million -20.2%7.8%8.7 $7.42 1/15/20222,720,000 shares $25.27 million -2.5%9.8%10.8 $9.29 12/31/20212,790,000 shares $33.17 million +0.4%10.0%15 $11.89 12/15/20212,780,000 shares $36.00 million +1.8%10.0%14 $12.95 11/30/20212,730,000 shares $38.79 million +2.6%9.8%12.1 $14.21 11/15/20212,660,000 shares $38.86 million +15.7%9.5%11.7 $14.61 10/29/20212,300,000 shares $33.37 million +7.0%8.3%10.4 $14.51 10/15/20212,150,000 shares $31.99 million +2.9%7.8%9.2 $14.88 9/30/20212,090,000 shares $33.94 million +26.7%7.6%8.7 $16.24 9/15/20211,650,000 shares $26.86 million +10.0%6.0%6.2 $16.28 8/31/20211,500,000 shares $25.40 million -32.4%5.4%6 $16.93 8/13/20212,220,000 shares $38.47 million +8.8%8.1%9.1 $17.33 7/30/20212,040,000 shares $36.86 million +9.1%7.4%8.3 $18.07 7/15/20211,870,000 shares $35.34 million +2.2%6.7%8.2 $18.90 6/30/20211,830,000 shares $38.50 million -0.5%6.8%7.4 $21.04 6/15/20211,840,000 shares $37.65 million No Change6.8%8.1 $20.46 5/28/20211,840,000 shares $35.16 million -3.2%6.8%8.1 $19.11 5/14/20211,900,000 shares $32.26 million +7.3%7.0%7.1 $16.98 4/30/20211,770,000 shares $33.98 million -10.6%6.5%5.9 $19.20Washington Thinks They Own Your Bank Account (Ad)What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.Get your free guide now by clicking here >> 4/15/20211,980,000 shares $33.98 million +11.2%7.2%5 $17.16 3/31/20211,780,000 shares $27.11 million -5.3%6.5%4 $15.23 3/15/20211,880,000 shares $31.66 million +8.7%6.9%3.9 $16.84 2/26/20211,730,000 shares $33.46 million +7.5%6.3%3.8 $19.34 2/12/20211,610,000 shares $30.28 million +11.0%5.9%3.7 $18.81 1/29/20211,450,000 shares $27.10 million +3.6%6.5%3.5 $18.69 1/15/20211,400,000 shares $40.67 million No Change6.3%3.5 $29.05 DYN Short Interest - Frequently Asked Questions What is Dyne Therapeutics' current short interest? Short interest is the volume of Dyne Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 15,730,000 shares of DYN short. Learn More on Dyne Therapeutics' current short interest. What is a good short interest ratio for Dyne Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DYN shares currently have a short interest ratio of 6.0. Learn More on Dyne Therapeutics's short interest ratio. Which institutional investors are shorting Dyne Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Dyne Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Dyne Therapeutics' short interest increasing or decreasing? Dyne Therapeutics saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 15,730,000 shares, a decrease of 3.9% from the previous total of 16,370,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Dyne Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Dyne Therapeutics: Rhythm Pharmaceuticals, Inc. (7.53%), Nuvalent, Inc. (12.35%), Axsome Therapeutics, Inc. (7.27%), CRISPR Therapeutics AG (27.82%), Lantheus Holdings, Inc. (12.25%), ADMA Biologics Inc (6.06%), Merus N.V. (6.56%), Abivax SA Sponsored ADR (2.57%), TG Therapeutics, Inc. (15.22%), Avidity Biosciences, Inc. (13.49%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Dyne Therapeutics stock? Short selling DYN is an investing strategy that aims to generate trading profit from Dyne Therapeutics as its price is falling. DYN shares are trading down $0.40 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Dyne Therapeutics? A short squeeze for Dyne Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DYN, which in turn drives the price of the stock up even further. How often is Dyne Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DYN, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Rhythm Pharmaceuticals Short Squeeze Nuvalent Short Squeeze Axsome Therapeutics Short Squeeze CRISPR Therapeutics Short Squeeze Lantheus Short Squeeze ADMA Biologics Short Squeeze Merus Short Squeeze Abivax Short Squeeze TG Therapeutics Short Squeeze Avidity Biosciences Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DYN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DYN Stock Alerts